These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32158424)

  • 1. Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience.
    Zanghì A; D'Amico E; Callari G; Chisari CG; Borriello G; Grimaldi LME; Patti F
    Front Neurol; 2020; 11():105. PubMed ID: 32158424
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.
    Hellwig K; Verdun di Cantogno E; Sabidó M
    Ther Adv Neurol Disord; 2021; 14():17562864211051012. PubMed ID: 34876925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic inertia in relapsing-remitting multiple sclerosis.
    Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
    Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    Haben S; Ciplea AI; Tokic M; Timmesfeld N; Thiel S; Gold R; Langer-Gould AM; Hellwig K
    J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):151-157. PubMed ID: 37536925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
    Bove R; Applebee A; Bawden K; Fine C; Shah A; Avila RL; Belviso N; Branco F; Fong K; Lewin JB; Liu J; England SM; Vignos M
    Mult Scler Relat Disord; 2024 Jun; 88():105738. PubMed ID: 38959591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
    J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
    Zafar A; AlShamrani FJG
    Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
    Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
    Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Yeh WZ; Widyastuti PA; Van der Walt A; Stankovich J; Havrdova E; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout BI; Lechner-Scott J; Sola P; Skibina OG; Barnett M; Onofrj M; Sá MJ; McCombe PA; Grammond P; Ampapa R; Grand'Maison F; Bergamaschi R; Spitaleri DLA; Van Pesch V; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Gresle M; Uher T; Maimone D; Turkoglu R; Hupperts RM; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell RA; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis VG;
    Neurology; 2021 Jun; 96(24):e2989-e3002. PubMed ID: 33879599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.
    Alroughani R; Alowayesh MS; Ahmed SF; Behbehani R; Al-Hashel J
    Neurology; 2018 Mar; 90(10):e840-e846. PubMed ID: 29429970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.
    Lescot L; Lefort M; Leguy S; Le Page E; Vukusic S; Edan G; Kerbrat A; Lebrun-Frenay C; De Sèze J; Laplaud DA; Wiertlewski S; Leray E; Michel L
    Mult Scler Relat Disord; 2022 Dec; 68():104122. PubMed ID: 36037756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.